Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.

Favier AL, Gout E, Reynard O, Ferraris O, Kleman JP, Volchkov V, Peyrefitte C, Thielens NM.

J Virol. 2016 May 12;90(11):5256-5269. doi: 10.1128/JVI.00232-16. Print 2016 Jun 1.

2.

Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.

Brudner M, Karpel M, Lear C, Chen L, Yantosca LM, Scully C, Sarraju A, Sokolovska A, Zariffard MR, Eisen DP, Mungall BA, Kotton DN, Omari A, Huang IC, Farzan M, Takahashi K, Stuart L, Stahl GL, Ezekowitz AB, Spear GT, Olinger GG, Schmidt EV, Michelow IC.

PLoS One. 2013;8(4):e60838. doi: 10.1371/journal.pone.0060838. Epub 2013 Apr 2.

3.
4.

Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.

Lennemann NJ, Rhein BA, Ndungo E, Chandran K, Qiu X, Maury W.

MBio. 2014 Jan 28;5(1):e00862-13. doi: 10.1128/mBio.00862-13.

5.

The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.

Brinkmann C, Nehlmeier I, Walendy-Gnirß K, Nehls J, González Hernández M, Hoffmann M, Qiu X, Takada A, Schindler M, Pöhlmann S.

J Virol. 2016 Nov 28;90(24):11075-11086. Print 2016 Dec 15.

6.

The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR.

Marzi A, Akhavan A, Simmons G, Gramberg T, Hofmann H, Bates P, Lingappa VR, Pöhlmann S.

J Virol. 2006 Jul;80(13):6305-17.

7.

Characterization of Human and Murine T-Cell Immunoglobulin Mucin Domain 4 (TIM-4) IgV Domain Residues Critical for Ebola Virus Entry.

Rhein BA, Brouillette RB, Schaack GA, Chiorini JA, Maury W.

J Virol. 2016 Jun 10;90(13):6097-6111. doi: 10.1128/JVI.00100-16. Print 2016 Jul 1.

8.

Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin.

Gustin JK, Bai Y, Moses AV, Douglas JL.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S181-90. doi: 10.1093/infdis/jiv125. Epub 2015 Mar 27.

9.

Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.

Olejnik J, Forero A, Deflubé LR, Hume AJ, Manhart WA, Nishida A, Marzi A, Katze MG, Ebihara H, Rasmussen AL, Mühlberger E.

J Virol. 2017 May 12;91(11). pii: e00179-17. doi: 10.1128/JVI.00179-17. Print 2017 Jun 1.

10.

Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway.

Spence JS, Krause TB, Mittler E, Jangra RK, Chandran K.

MBio. 2016 Feb 9;7(1):e01857-15. doi: 10.1128/mBio.01857-15.

11.

Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection.

Zhang X, Ao Z, Bello A, Ran X, Liu S, Wigle J, Kobinger G, Yao X.

Antiviral Res. 2016 Mar;127:20-31. doi: 10.1016/j.antiviral.2016.01.001. Epub 2016 Jan 9.

PMID:
26778707
12.

Novel Small Molecule Entry Inhibitors of Ebola Virus.

Basu A, Mills DM, Mitchell D, Ndungo E, Williams JD, Herbert AS, Dye JM, Moir DT, Chandran K, Patterson JL, Rong L, Bowlin TL.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S425-34. doi: 10.1093/infdis/jiv223. Epub 2015 Jul 22.

13.

A Polymorphism within the Internal Fusion Loop of the Ebola Virus Glycoprotein Modulates Host Cell Entry.

Hoffmann M, Crone L, Dietzel E, Paijo J, González-Hernández M, Nehlmeier I, Kalinke U, Becker S, Pöhlmann S.

J Virol. 2017 Apr 13;91(9). pii: e00177-17. doi: 10.1128/JVI.00177-17. Print 2017 May 1.

14.

Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies.

Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE Jr, Chandran K, Saphire EO.

MBio. 2016 Feb 23;7(1):e02154-15. doi: 10.1128/mBio.02154-15.

15.

Shedding of Ebola Virus Surface Glycoprotein Is a Mechanism of Self-regulation of Cellular Cytotoxicity and Has a Direct Effect on Virus Infectivity.

Dolnik O, Volchkova VA, Escudero-Perez B, Lawrence P, Klenk HD, Volchkov VE.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S322-8. doi: 10.1093/infdis/jiv268. Epub 2015 Jun 19.

PMID:
26092855
16.

Analysis of Ebola Virus Entry Into Macrophages.

Dahlmann F, Biedenkopf N, Babler A, Jahnen-Dechent W, Karsten CB, Gnirß K, Schneider H, Wrensch F, O'Callaghan CA, Bertram S, Herrler G, Becker S, Pöhlmann S, Hofmann-Winkler H.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S247-57. doi: 10.1093/infdis/jiv140. Epub 2015 Apr 14.

17.

A novel L-ficolin/mannose-binding lectin chimeric molecule with enhanced activity against Ebola virus.

Michelow IC, Dong M, Mungall BA, Yantosca LM, Lear C, Ji X, Karpel M, Rootes CL, Brudner M, Houen G, Eisen DP, Kinane TB, Takahashi K, Stahl GL, Olinger GG, Spear GT, Ezekowitz RA, Schmidt EV.

J Biol Chem. 2010 Aug 6;285(32):24729-39. doi: 10.1074/jbc.M110.106260. Epub 2010 Jun 1.

18.

Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection.

Okumura A, Rasmussen AL, Halfmann P, Feldmann F, Yoshimura A, Feldmann H, Kawaoka Y, Harty RN, Katze MG.

J Virol. 2015 Oct;89(20):10399-406. doi: 10.1128/JVI.01736-15. Epub 2015 Aug 5.

19.

Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity.

Kaletsky RL, Simmons G, Bates P.

J Virol. 2007 Dec;81(24):13378-84. Epub 2007 Oct 10.

20.

ALIX Rescues Budding of a Double PTAP/PPEY L-Domain Deletion Mutant of Ebola VP40: A Role for ALIX in Ebola Virus Egress.

Han Z, Madara JJ, Liu Y, Liu W, Ruthel G, Freedman BD, Harty RN.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S138-45. doi: 10.1093/infdis/jiu838. Epub 2015 Mar 18.

Supplemental Content

Support Center